Salinomycin Induces Cell Cycle Arrest and Apoptosis and Modulates Hepatic Cytochrome P450 MRNA Expression in HepG2/C3a Cells
Overview
Authors
Affiliations
Salinomycin (SAL) is a monocarboxylic polyether ionophore antibiotic isolated from . It exhibits an effective antitumor potential against numerous human cancer cells. This study aimed to assess the antiproliferative effects of SAL in human hepatocellular carcinoma HepG2/C3a cell line. We investigated the effects of SAL on cell growth, DNA damage induction, cell cycle changes and apoptosis; and relative changes in expression of cell cycle-related, apoptosis-related, and CYP450 genes. SAL induced cell cycle arrest in the G2/M phase, upregulation of and and downregulation of cyclin genes including and SAL effectively suppressed mRNA levels of gene, an important oncogene that promotes tumorigenesis. The decrease of HepG2/C3A cells' survival can also be due to downregulation of antiapoptotic expression, thus promoting the induction of apoptosis by SAL. This study also demonstrated the ability of SAL in modulating hepatic cytochrome P450 (CYP) mRNA expression, such that SAL caused the upregulation of members and ; and downregulation of . Taken together, these data contribute to the understanding of the mechanism of action of SAL, highlighting that metabolizing enzymes modulated by SAL can interfere with chemotherapy treatment and it must be considered in associated treatments.
Degirmenci N, Padar G, Sahin F, Omeroglu Ulu Z Biol Trace Elem Res. 2024; .
PMID: 39441231 DOI: 10.1007/s12011-024-04416-w.
Min Y, Li Q, Yu H, Du S Mar Life Sci Technol. 2024; 6(3):488-501.
PMID: 39219677 PMC: 11358575. DOI: 10.1007/s42995-024-00221-5.
Chuang Y, Yen C, Chien T, Chang F, Tsai Y, Wu K Int J Mol Sci. 2024; 25(11).
PMID: 38892270 PMC: 11173094. DOI: 10.3390/ijms25116083.
Liu M, Li H, Huo Z, Chen H, Kang X, Xu B Appl Biochem Biotechnol. 2023; 196(6):3184-3198.
PMID: 37632659 DOI: 10.1007/s12010-023-04699-0.
Wnt signaling in liver regeneration, disease, and cancer.
Zou G, Park J Clin Mol Hepatol. 2022; 29(1):33-50.
PMID: 35785913 PMC: 9845677. DOI: 10.3350/cmh.2022.0058.